Increased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumor

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Angiogenesis is crucial for malignant tumor development.
• Targeting tumor angiogenesis is a key strategy in cancer gene therapy.
• The anti-angiogenesis protein K5 (kringle 5 of human plasminogen) has therapeutic potential.

Purpose of the Study:

• To engineer and evaluate a novel oncolytic adenovirus, ZD55-mK5, expressing a mutated K5 protein (mK5).
• To assess the anti-angiogenic and anti-tumor efficacy of ZD55-mK5.
• To determine the potential of ZD55-mK5 in cancer gene therapy.

Main Methods:

• Mutation of K5 protein (leucine71 to arginine) to create mK5.
• Construction of an oncolytic adenovirus expressing mK5 (ZD55-mK5).
• In vitro assays: human umbilical vein endothelial cell proliferation, tube formation.
• In vivo assays: embryonic chorioallantoic membrane assay, colorectal tumor xenograft growth suppression in nude mice.

Main Results:

• ZD55-mK5 demonstrated enhanced inhibition of endothelial cell proliferation compared to ZD55-K5.
• ZD55-mK5 showed superior anti-angiogenic effects in tube formation and embryonic chorioallantoic membrane assays.
• ZD55-mK5 significantly suppressed colorectal tumor xenograft growth and prolonged survival in nude mice.

Conclusions:

• The engineered mK5 protein exhibits potent anti-angiogenic properties.
• ZD55-mK5 is an effective oncolytic adenovirus for inhibiting tumor angiogenesis and growth.
• ZD55-mK5 represents a promising candidate for cancer gene therapy targeting angiogenesis.